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Abstract 1 
Background – Connective tissue disease (CTDs) associated interstitial lung disease (ILD) often fails to 2 
respond to conventional immuno-modulatory agents.  This has led to the exploration of Rituximab, which 3 
has shown benefit for other aspects of these diseases, in patients refractory to standard treatments. 4 
Methods – We conducted a retrospective analysis of all patients who received Rituximab under the Bristol 5 
ILD service, having failed to respond to other immuno-modulatory treatments.  Results were collated for 6 
pulmonary function and radiological outcomes before and after treatment. 7 
Results – 24 patients were managed with Rituximab.  Their physiological parameters had failed to improve 8 
despite other immuno-modulatory agents with a mean change in FVC prior to therapy of -3.3% (95% CI, -9 
5.6 to -1.1%) and mean DLCO change of -4.3% (95% CI, -7.7 to -0.9%).  After Rituximab, radiology remained 10 
stable or improved for 11, while worsening was observed in 9 patients.  The decline in FVC was reversed 11 
following treatment, with a mean change of +4.1% (95% CI, 0.9 to 7.2%), while DLCO was stable (mean 12 
change +2.1% (95% CI, -1.0 to 5.2%).  Patients with myositis or anti-synthetase syndrome appeared to 13 
respond well to treatment, with 4 patients showing clinically significant improvement in FVC >10%. 14 
Conclusions – Rituximab is a therapeutic option in treatment refractory CTD-associated ILD.  Some disease 15 
subgroups may respond better than others, however more work is needed to define its role in managing 16 
these patients. 17 
  18 
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Rituximab in autoimmune connective tissue disease-associated interstitial lung disease 1 
Introduction 2 
An increased understanding of the molecular pathways of inflammation and autoimmunity has led to the 3 
development of targeted biological agents and expanded the repertoire of treatment options in the 4 
autoimmune connective tissue diseases (CTDs).  Lymphocyte-targeted therapies, including the anti-CD20 B-5 
cell depleting monoclonal antibody, Rituximab are now used in clinical practice for diseases such as 6 
rheumatoid arthritis and systemic lupus erythematous (SLE) and refractory anti-neutrophil cytoplasmic 7 
antibody-associated (ANCA +ve) vasculitis[1-3]. This has led to exploration of its use in CTD-associated 8 
interstitial lung diseases (ILD) in patients deteriorating despite other immunosuppressive therapy.  Evidence 9 
for this approach is based on institutional experiences, with no randomised, controlled trials yet published. 10 
The CTDs are heterogeneous processes characterised by autoimmune-mediated inflammation targeting 11 
various organ systems with resultant end-organ damage [4].  A more detailed description of CTDs is beyond 12 
the scope of this introduction, readers are directed to the cited reviews[5, 4].  One mechanism of action of 13 
Rituximab is thought to be through depletion of CD20 +ve B-lymphocytes, thereby inhibiting their 14 
differentiation into antibody producing cells and T-cell co-stimulation. Translational studies have highlighted 15 
other mechanisms, which are being further investigated[6].   16 
It is recognised that all patients with CTDs are at risk of ILD, some more so than others[5].  While this ILD 17 
may be subclinical, having been identified through both radiological appearances and lung function 18 
abnormalities in 33-57% of CTD patients with no respiratory symptoms[7-10], 5-80% of patients go on to 19 
develop clinically significant lung disease within 3 years, with variation depending on the specific CTD.  The 20 
radiological and histological pattern of ILD described varies depending on the underlying CTD (Table 1), 21 
reflecting the heterogeneity of these conditions.   22 
The Bristol Interstitial Lung Disease service runs a combined service with the Rheumatology CTD team to 23 
manage patients with progressive lung disease and over the last 5 years has developed extensive experience 24 
5 
 
managing these patients with immunosuppression; typically including oral immuno-modulatory agents, 1 
intravenous (IV) Methylprednisolone and IV Cyclophosphamide.  The aims of management in this population 2 
of patients are, where possible, to reverse disease progression and decisions to initiate B-cell depletion with 3 
Rituximab are implemented through a defined pathway.  These decisions are based on a combination of 4 
clinical or radiological deterioration, or attenuation of a previous improvement with immune-modulatory 5 
treatment.  This is a report of our experience. 6 
 7 
Methods and materials 8 
Patient selection 9 
Review of our clinical database identified twenty four patients managed in the combined ILD-Rheumatology 10 
/ CTD clinic treated with Rituximab.  Diagnosis of diffuse parenchymal lung disease was in accordance with 11 
British Thoracic Society Interstitial Lung Disease guidelines[11], with biopsies used where clinically indicated.  12 
CTDs were diagnosed based on accepted international criteria.  A subgroup of patients were identified with 13 
myositis or the anti-synthetase syndrome for separate analysis.  Patients with Rheumatoid arthritis were 14 
excluded due to the distinct pattern of ILD observed in this group. 15 
Hospital records were reviewed to identify, pulmonary function tests (PFT) performed 5 to 7 months prior 16 
to Rituximab, in the 4 weeks immediately beforetreatment and 6 to 12 months following treatment.  Where 17 
relevant, the same approach was taken to PFTs prior to, at treatment with and following cyclophosphamide 18 
therapy.  High resolution computed tomograms (HRCT) of the chest were identified from time of treatment 19 
and during follow-up.  Patients were followed for a median of 29.6 months (16.7).  All PFT measurements 20 
were performed within the same respiratory physiology laboratory.   21 
This clinical review was performed with full ethical approval (Reference 15/EE/0023). 22 
Imaging 23 
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HRCTs were performed for clinical reasons.  Images were reconstructed on a standard HRCT algorithm and 1 
interspaced 1mm slices reviewed on lung window settings were assessed on two separate occasions, 6 2 
months apart, by an experienced ILD Thoracic Radiologist blinded to treatment and therapy.  Overall extent 3 
of interstitial pathology, in addition to the ground glass component, was evaluated and quantified according 4 
to the visual estimation of extent of involvement described by Oda et al[12].  Change, compared with 5 
baseline imaging, after treatment was assessed and categorised as: improved, stable or worsened.  The κ 6 
value for intra-rater agreement for extent of disease was 0.55, with a value of 0.92 for interval change. 7 
Statistical analysis 8 
Values are shown as mean with standard deviation (SD), mean difference with confidence intervals or 9 
frequencies as appropriate.  Changes in PFTs and radiological extent are expressed as percentage change 10 
from start of therapy.  Changes in values before, at the time of, and after treatment were assessed for 11 
normality and analysed with one-sample t-test using a test value of 0 or paired t-test as appropriate.  12 
Categorical variables were analysed using Chi-square testing.  All analyses used a p-value of <0.05 as the 13 
threshold for statistical significance.  Analyses were performed using SPSS software (v21.0.0; IBM Corp.; 14 
Armonk, NY, USA). 15 
Results 16 
 17 
Twenty four patients (16 female), with a mean age of 51.4 yrs (SD 14.9), were treated with Rituximab 18 
between October 2009 and January 2015.  12/24 patients were former smokers. The mean duration of 19 
follow-up after treatment was 29.6 months (16.7). Biopsy had been performed in 11/24 patients.  Patient 20 
characteristics are shown in Table 2. 21 
 22 
These patients were all managed under the ILD-Rheumatology/CTD service and all had a diagnosis of CTD-23 
ILD. Twenty two patients had positive serology for autoimmune markers (Table 3).  The diagnoses were 24 
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reached through correlation of clinical, serological, radiological and histopathological data, with diagnoses 1 
confirmed through consensus in a multidisciplinary ILD-CTD forum involving Clinicians, Radiologists and 2 
Pathologists.  3 
 4 
Pre-Rituximab Disease course and treatment (Figure 1) 5 
  6 
All patients had failed to respond adequately to prior immunosuppressive therapies, including induction with 7 
pulsed intravenous Cyclophosphamide in 16 patients (at a dose of 15mg/kg, capped at 1 gram, for 6 cycles, 8 
at 3 week intervals) with IV methylprednisolone (500mg-1g prior to each dose of Cyclophosphamide) and 9 
Mycophenolate mofetil in 10 patients.  Details of the treatments given and the interval to rituximab are given 10 
in table 4.   11 
 12 
FVC and DLCO had failed to improve despite treatment prior to Rituximab.  Mean change in FVC was -3.3% 13 
(p=0.005, 95% CI, -5.6 to -1.1%), with mean DLCO change of -4.3% (p=0.02, 95% CI, -7.7 to -0.9%).  Of those 14 
treated with Cyclophosphamide, this did not reverse disease trajectory; mean change in FVC following pulsed 15 
intravenous treatment was -1.2% (p=0.51, 95% CI, -5.2 to +2.7%), mean change in DLCO was +1.3% (p=0.54, 16 
95% CI, -3.1 to +5.7%). 17 
 18 
CTs were available for review for all patients prior to treatment. On HRCT, mean disease extent was 40.8% 19 
(SD 20.3%) of the lung, with ground glass change representing a mean 55.6% (SD 36.3%) of affected areas.  20 
The radiological patterns for each patient are shown in Table 5.  21 patients had more than one CT available, 21 
enabling assessment of interval change prior to treatment.  Radiological appearances were deteriorating for 22 
8 patients, had failed to improve for 11 patients.  For the two patients whose imaging had improved, the 23 
MDT assessment was that there was further scope for improvement. 24 
 25 
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Decision to treat 1 
 2 
The decision to commence Rituximab treatment was based on multidisciplinary discussion and a synthesis 3 
of features including: 4 
 Progressive lung function decline 5 
 Progression or lack of improvement in rheumatological features despite treatment 6 
 Radiological changes; either progressive changes or a failure of disease adjudged as reversible to 7 
improve or resolve (for example ground glass changes) 8 
 9 
Rituximab administration 10 
 11 
Rituximab was administered according to rheumatology/CTD protocol, at a dose of 1 gram intravenously 12 
infused at days 0 and 14.  Following treatment, oral immunosuppression was continued in all patients.   13 
 14 
Post-treatment disease course (Figure 1) 15 
Pulmonary function testing data both before and after treatment were available for all patients.  FVC 16 
improved following treatment, with a mean change of 4.1% (p=0.01, 95% CI, 0.9 to 7.2%).  DLCO remained 17 
stable with a mean change of 2.1% (p=0.18, 95% CI, -1.0 to 5.2%).  Four patients demonstrated clinically 18 
meaningful improvements of >10% in their FVC following treatment (Figure 1).  When comparing pre- and 19 
post-treatment disease trajectory, Rituximab reversed previous trends in lung function change for both FVC 20 
(p=0.001) and DLCO (p=0.02). 21 
 22 
HRCT imaging following treatment was available for 22 patients.  One patient died before interval imaging 23 
was completed and one patient with myositis-related lung disease has insufficient followup to merit interval 24 
imaging.  The mean change in disease extent was -3.75% (p=0.33, 95% CI -11.6 to 4.1).  By radiological 25 
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criteria, the imaging had deteriorated for 9/22 patients, with 13/22 showing disease stability or 1 
improvement following treatment.  Chi-square analysis comparing the trend in radiological appearances 2 
before and after treatment demonstrated no significant differences (χ2 5.695, p=0.223). 3 
 4 
Myositis and anti-synthetase subgroup (Figure 2, Table 6) 5 
Thirteen patients (9 female) were identified with myositis or the anti-synthetase syndrome, with a mean age 6 
of 53.5 yrs (SD 13.2).  Seven of these were former smokers.  They had physiological impairment at baseline 7 
with a mean FVC of 75.3% predicted (SD 17.0%) and mean DLCO 55.9% predicted (SD 16.4%).  On initial HRCT 8 
imaging, mean extent of disease was 37.3% (SD 19.2%) with ground glass representing 52.7% (SD 34.4%) of 9 
this disease.  Treatment prior to Rituximab did not arrest deterioration in physiological parameters.  These 10 
trends were not significantly different to those with other diagnoses. 11 
 12 
Following treatment, FVC and DLCO both improved statistically by a significantly greater extent than in those 13 
patients with alternative diagnoses.  Four patients in the myositis group demonstrated improvement in their 14 
FVC >10%, showing a clinically meaningful improvement.  Radiological appearances were assessed as 15 
improved in 3/11 patients, with worsening of disease only adjudged in one patient.  16 
 17 
When comparing patients with myositis or anti-synthetase syndrome with the remaining group, there were 18 
significant differences in the response to treatment.  FVC change after treatment was greater in the myositis 19 
sub-group (p=0.002), as was improvement in DLCO (p=0.009).  There were no other significant between group 20 
differences. 21 
 22 
Adverse events 23 
There were no complications observed associated with treatment.  One patient died due to disease 24 
progression four months after treatment.  25 
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 1 
Discussion 2 
We report here our experience of Rituximab in CTD-ILD in a significant number of patients, including an 3 
identified cohort with myositis/overlap syndromes.  This report adds to very limited published data for use 4 
of B-cell depletion as treatment in this difficult disease group.   5 
The decision to treat is multi-factorial, guided by a combination of respiratory parameters and also 6 
rheumatological considerations.  One unanswered question, and one which will prove challenging in the 7 
context of clinical trials, is the means of defining treatment success.  In some patients the aim of treatment 8 
is to arrest or slow decline, whilst in others the aim is to reverse disease.  In patients with CTD-ILD, namely 9 
SSc and overlap myositis, one could debate that disease stability or lack of progression is a marker of 10 
treatment response.  11 
Also a consideration is the natural history of disease.  Where endothelial injury has occurred, resulting in the 12 
beginnings of fibrosis, the mesenchymal cells within later fibroblastic foci may begin to drive progressive 13 
fibrosis.  Treatment aimed at arresting the autoimmune injury prior to this is the rationale behind aggressive 14 
treatment in early disease.  The clinical data for disease course and natural history of CTD-ILD is lacking 15 
however. 16 
Our data demonstrates, consistent with previously published series, a numerical improvement in FVC, with 17 
stability of DLCO, however no impact was seen on radiological appearances.  It is important to highlight that 18 
these improvements were only clinically significant in four patients.  These “responders” were patients with 19 
myositis or anti-synthetase syndrome-related lung disease and this group appear to respond particularly well 20 
to treatment, with greater improvement in FVC and DLCO compared to the non-myositis group.   21 
The limitations to our data are their observational nature, and the heterogeneity of data captured in the 22 
course of disease.  Despite this, we have observed statistically significant benefit in these patients and 23 
clinically relevant benefit in a subgroup. 24 
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Preliminary reports including case reports and series have suggested that B cell depletion is a potential 1 
therapeutic target in CTD-ILD. The first report of successful treatment of Systemic Sclerosis (SSc)-associated 2 
ILD with Rituximab was in 2008[13], with further experience reported in a cohort of 8 patients, in whom the 3 
FVC and diffusing capacity of carbon monoxide (DLCO) increased significantly more than a matched cohort 4 
receiving standard treatment[14].  In addition, a further study has highlighted the potential role of Rituximab 5 
in the anti-synthetase syndrome; 11 patients with severe and progressive ILD, who had failed to improve 6 
with Cyclophosphamide, demonstrated stabilisation of their lung disease based on forced vital capacity 7 
(FVC), DLCO and high resolution computed tomography appearances[15]. 8 
Keir and colleagues have reported their experience of Rituximab in a more diverse cohort of 50 patients with 9 
ILD of various aetiologies, including CTD-ILD and also hypersensitivity pneumonitis and smoking-related 10 
ILDs[16].  They reported a median improvement in FVC in the 6-12 months following treatment of 6.7%, with 11 
stability of DLCO.  The FVC in a subgroup of 33 patients with CTD-ILD, improved by 8.9%.  Their results 12 
suggested a role for anti-CD20 B cell therapies in CTD-ILD and possibly a wider role in other ILDs. 13 
A subset of CTD patients with inflammatory myositis have been recognised to have a high risk of ILD.  This 14 
group of diseases includes the anti-synthetase syndrome (ASS), which is characterised by auto-antibodies 15 
against the aminoacyl-tRNA synthetases, including anti-Jo1, anti-PL7 and anti-PL12.  This clinical syndrome 16 
is characterised by prominent ILD, with accompanying myositis, cutaneous changes including “mechanic’s 17 
hands”, fevers and non-erosive arthritis[17].  A number of factors in this group have been linked with the 18 
development and severity of ILD, including Asian ethnicity, those with severe skin involvement, minimal or 19 
no clinical muscle weakness and pyrexia.  This group of patients may also manifest ILD as their first 20 
presentation of CTD.  In one cohort, 15% of new patients referred to a tertiary referral centre met diagnostic 21 
criteria for CTDs[18]. 22 
Our observed response to Rituximab therapy in a myositis-overlap group complements the findings of the 23 
RIM study[19].  This large randomised, controlled trial of early (at weeks 0 and 1), compared to late (at weeks 24 
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8 and 9) Rituximab in treatment-refractory myositis found no difference in the primary end point of time to 1 
achieve the International Myositis Assessment and Clinical Studies Group preliminary definition of 2 
improvement. This is likely to have been due to study design, as 83% of patients had achieved the primary 3 
outcome by 20 weeks from randomisation.  A subgroup analysis demonstrated that presence of anti-4 
synthetase autoantibodies was a strong predictor of improvement with treatment[20]. 5 
This adds to the weight of evidence of the heterogeneity of CTD-ILD, and also further underscores the need 6 
for further research in this group of patients for whom there is little robust evidence for treatment.  The 7 
RECITAL study, a randomised, controlled trial comparing Rituximab to Cyclophosphamide in CTD-ILD 8 
(clinicaltrials.gov identifier: NCT01862926) is designed to address this important question.  A further 9 
resource, which would be of value in this field by pooling data such as ours, would be a registry for CTD-ILD. 10 
Data such as ours remains central to providing evidence to support the decision to use agents such as 11 
Rituximab in these patients and in the absence of published clinical trials is vital to support decision making, 12 
including those surrounding clinical commissioning within the NHS in England. 13 
In conclusion, we present here our experience using Rituximab for treatment-refractory CTD-ILD.  Rituximab 14 
has arrested previous decline in lung function in this cohort, with particular benefit seen in a subgroup of 15 
patients with myositis-overlap syndromes.  The role of Rituximab in CTD-ILD remains to be defined and our 16 
data highlights the need for more research to identify those patients who will have the best response to 17 
treatment. 18 
Key messages 19 
 Rituximab appeared to reverse previously declining lung function in patients with connective tissue disease-20 
associated interstitial lung disease 21 
 A subgroup of patients with myositis-overlap syndromes, including the anti-synthetase syndrome appeared 22 
to respond particularly to Rituximab. 23 
 Further research is needed to identify which patient groups will benefit from Rituximab. 24 
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Figure Legends 15 
Figure 1 – Changes in lung function before and after treatment 16 
FVC – Forced vital capacity, DLCO – Diffusing capacity for carbon monoxide. *p=0.001, **p=0.02 17 
 18 
Figure 2 – Comparison of myositis subgroup and other patients’ response to treatment 19 
FVC – Forced vital capacity, DLCO – Diffusing capacity for Carbon Monoxide. * p<0.01 20 
 21 
  22 
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Tables 1 
Table 1 – Incidence of subtypes of ILD in CTD 2 
 Patients 
with 
lung 
involve
ment 
UIP NSIP COP DAD LIP DAH 
Systemic sclerosis 20-65% ++ ++++ + + - - 
Rheumatoid arthritis ~70% ++ + - + - - 
Mixed connective 
tissue disease 
20-80% ++ +++ - - + - 
Systemic lupus 
erythematosus 
50-60% + + + ++ - +++ 
Inflammatory 
myositis-CTD 
overlap* 
~75% ++ ++++ ++ + - - 
Primary Sjogren’s 
syndrome 
10-30% + + + - +++ - 
 (Lowest (-) to highest (++++)).   
UIP (Usual Interstitial Pneumonia), NSIP (Non-specific Interstitial Pneumonia), COP (Cryptogenic 
Organising Pneumonia), DAD (Diffuse Alveolar Damage), LIP (Lymphocytic Interstitial Pneumonia), 
DAH (Diffuse Alveolar Haemorrhage). 
*Includes Anti-synthetase syndrome, dermatomyositis and overlap myositis. 
 3 
  4 
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Table 2 – Baseline characteristics of patients 1 
Demographics  
Age 51.4 (14.9) 
Female 16 (66.7%) 
Ex-smokers 12 (50%) 
Oxygen use 5/24 
Diagnosis  
Anti-synthetase syndrome (ASS) 10 
Dermatomyositis (other / non-ASS) 3 
Systemic sclerosis 3 
Sjögren’s syndrome 2 
SLE 2 
Unclassifiable CTD-ILD  4 
Biopsy 11/24 
Histopathological pattern  
NSIP 9 
LIP 1 
Hypersensitivity Pneumonitis 1 
Identified auto-antibodies (see Table 3) 22/24 
Treatments  
Cyclophosphamide 16 
IV Methylprednisolone 16 
Mycophenolate mofetil 9 
Hydroxychloroquine 2 
Azathioprine 4 
Methotrexate 1 
Physiology  
FVC (% pred) 78.4 (21.4) 
FEV1 (% pred) 75.4 (18.6) 
FEV1/FVC ratio 0.81 (0.06) 
DLCO (% pred) 50.9 (18.0) 
SO2 (%) 96 (1.5) 
SLE – Systemic Lupus Erythematous, NSIP – Non-specific Interstitial Pneumonia, LIP – 
Lymphocytic Interstitial Pneumonia, FVC – Forced Vital Capacity, FEV1 – Forced Expiratory 
Volume in 1 second, DLCO – Diffusing Capacity for Carbon Monoxide, SO2 – Oxygen 
Saturations 
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Table 3 – Patient diagnoses and auto-immune profiles 1 
Patient Age Gender Diagnosis Radiological 
pattern 
Histopathological 
pattern 
Extractable 
Nuclear 
Antibodies 
1 40.2 Male Scleroderma NSIP Fibrotic NSIP Scl70 
2 61.0 Female Dermatomyositis NSIP/OP   
3 67.6 Female Anti-synthetase NSIP  RNP, Jo1 
4 62.0 Male Anti-synthetase NSIP/OP 
Cellular/Fibrotic 
NSIP 
EJ 
5 37.7 Female Anti-synthetase NSIP  Jo1 
6 73.0 Male Dermatomyositis NSIP  PM-Scl 
7 49.1 Female Anti-synthetase NSIP/OP  Jo1 
8 59.5 Female Anti-synthetase NSIP/OP   
9 68.4 Female SLE NSIP  dsDNA 
10 29.7 Female Dermatomyositis NSIP  MDA5 
11 25.3 Female Scleroderma NSIP Fibrotic NSIP Ro, Scl70 
12 40.7 Female SLE OP   
13 48.8 Female Anti-synthetase NSIP/OP  Jo1 
14 36.8 Female Sjogrens LIP LIP Ro, La 
15 36.2 Female Anti-synthetase NSIP/OP Cellular NSIP PL-7 
16 21.0 Male Scleroderma NSIP Fibrotic NSIP Scl70 
17 51.8 Female Unclassifiable CTILD NSIP Fibrotic NSIP  
18 64.7 Female Anti-synthetase NSIP Fibrotic NSIP PM-Scl 
19 57.0 Female Unclassifiable CTILD LIP Fibrotic NSIP  
20 47.8 Male Anti-synthetase NSIP/OP Fibrotic NSIP PM-Scl 
21 58.8 Male Anti-synthetase NSIP  PL-12 
22 60.8 Male Unclassifiable CTILD Possible UIP   
23 68.3 Male Unclassifiable CTILD NSIP   
24 66.4 Female Sjogrens NSIP 
Hypersenstitivity 
pneumonitis 
RNP, Sm, 
dsDNA 
NSIP – Non-specific Interstitial Pneumonia, LIP – Lymphocytic Interstitial Pneumonia, OP, organising 
pneumonia, SLE – Systemic Lupus Erythematous 
 2 
  3 
18 
 
Table 4 – Patient treatment prior to Rituximab 1 
Patient Diagnosis Pre-Rituximab treatment Duration of treatment Comments 
1 Scleroderma   
Patient presented in 
extremis and treated 
urgently 
2 Dermatomyositis 
Previous oral cyclophosphamide, then 
MMF* >2 years 
 
3 Anti-synthetase 
IV cyclophosphamide and 
methylprednisolone, then azathioprine* 12 months 
 
4 Anti-synthetase 
IV methylprednisolone and 
cyclophosphamide, then MMF* 10 months 
 
5 Anti-synthetase IV cyclophosphamide, then MMF* 24 months  
6 Dermatomyositis IV cyclophosphamide 6 months  
7 Anti-synthetase IV cyclophosphamide, then MMF* 9 months  
8 Anti-synthetase 
IV cyclophosphamide, then 
azathioprine*and hydroxychloroquine* 12 months 
 
9 SLE Hydroxychloroqine* >2 years 
Unable to tolerate 
cyclophosphamide 
10 Dermatomyositis IV cyclophosphamide 21 months  
11 Scleroderma 
IV cyclophosphamide, then MMF*, with 
previous hydroxychloroquine and 
methotrexate 13 months 
 
12 SLE MMF* and hydroxychloroquine* >2 years  
13 Anti-synthetase IV cyclophosphamide, then MMF* 9 months  
14 Sjogrens 
IV cyclophosphamide and 
methylprednisolone, then azathioprine* 
and hydroxychloroquine* 10 months 
 
15 Anti-synthetase IV cyclophosphamide 20 months  
16 Scleroderma IV cyclophosphamide, then MMF* 7 months  
17 Unclassifiable CTILD IV cyclophosphamide, then MMF* 11 months  
18 Anti-synthetase IV cyclophosphamide 12 months  
19 Unclassifiable CTILD Methotrexate* >2 years  
20 Anti-synthetase IV cyclophosphamide, then MMF* 12 months  
21 Anti-synthetase 
IV methylprednisolone, then oral 
cyclophosphamide 18 months 
 
22 Unclassifiable CTILD IV cyclophosphamide 9 months  
23 Unclassifiable CTILD Methotrexate* 10 months  
24 Sjogrens   
Unable to tolerate 
cyclophosphamide 
The ongoing treatment at the time of Rituximab is indicated by *.  All patients had received varying doses of oral 
prednisolone.  Where no oral treatment is stated, prednisolone was ongoing. 
NSIP – Non-specific Interstitial Pneumonia, LIP – Lymphocytic Interstitial Pneumonia, OP, organising pneumonia, SLE – 
Systemic Lupus Erythematous, MMF – Mycophenolate mofetil, IV - intravenous 
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Table 5 – Radiological pattern, extent of disease and response to treatment 1 
Patient Pattern Disease 
Extent 
(%) 
Ground 
glass (% 
extent 
within 
fibrosis) 
Traction 
change 
Improvement
/worsening 
Change in 
extent 
after 
treatment 
(%) 
 1 Cellular 
NSIP 
70 100 None Worse 5 
 2 NSIP/OP 15 0 None No change 5 
 3 NSIP 25 75 Mild Better -10 
 4 NSIP/OP 40 20 Mild No change 0 
 5 NSIP 30 90 None Worse 0 
 6 NSIP 10 50 None No change 0 
 7 NSIP/OP 50 0 None No change 0 
 8 NSIP/OP 20 40 Mild No change 0 
 9 NSIP 70 50 Moderate Worse 10 
 10 NSIP 25 80 None No change 0 
 11 NSIP 75 80 None Worse 0 
 12 OP 15 0 None Worse 0 
 13 NSIP/OP 70 100 None Better -40 
 14 LIP 30 100 None Worse 20 
 15 NSIP/OP 45 40 None   
 16 NSIP 40 100 None Worse 15 
 17 NSIP 30 90 None Worse 10 
 18 NSIP 50 50 Mild   
 19 LIP 50 0 None No change 0 
 20 NSIP/OP 35 40 None No change 0 
 21 NSIP 70 100 None Better -40 
22 Possible 
UIP 
40 10 Moderate  -40 
23 NSIP 60 60 Mild Worse 20 
24 NSIP 15 60 Mild No change 0 
NSIP – Non-specific Interstitial Pneumonia, LIP – Lymphocytic Interstitial Pneumonia, OP, 
organising pneumonia, UIP – Usual Interstitial Pneumonia 
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Table 6 – Comparison of treatment effects in myositis and non-myositis group of patients 1 
 Myositis group Non-myositis group p-value 
Mean SD Mean SD 
FVC 
change 
(%) 
Before 
treatment 
-3.5 6.5 -3.1 3.7 0.84 
After 
treatment 
8.3 4.7 -0.9 7.3 0.002 
DLCO 
change 
(%) 
Before 
treatment 
-2.2 5.7 -6.8 10.0 0.19 
After 
treatment 
5.5 6.8 -2.0 5.9 0.009 
Change in disease extent 
on CT (%) 
-10.0 18.4 3.6 16.4 0.068 
FVC – Forced Vital Capacity, DLCO – Diffusing Capacity for Carbon Monoxide 
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